Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects

Inclusion Criteria: * Men or women of nonchildbearing potential between 18-70 years of age * Body Mass Index (BMI): 18.0 - 38.0 kg/m2. * Healthy subjects: in good health, determined by no clinically significant findings from clinical evaluations * Hepatic impairment subjects: confirmed hepatic impairment \>1 year with etiology of chronic alcoholism, chronic viral hepatitis (B or C), nonalcoholic steatohepatitis, autoimmune hepatitis, Wilson disease, alpha-1 antitrypsin deficiency, glycogen storage diseases, or galactosemia * Provided written informed consent prior to any study specific procedures Exclusion Criteria: * Women of childbearing potential * Hepatic impairment subjects: fluctuating or rapidly deteriorating hepatic function, acute hepatitis, variceal bleeding within 8 weeks of screening, a history of pancreatitis within 8 weeks of screening, evidence of hepatic encephalopathy \> Grade 1, current unstable hematologic condition, and/or creatinine clearance \< 60 mL/min * Healthy subjects: positive screening test for hepatitis B surface antigen, or hepatitis C antibody * ECG at screening or Day -1 showing QTcF ≥ 450 msec for healthy subjects or \> 500 msec for hepatically impaired subjects * Evidence of clinically significant medical conditions * History of gastrointestinal disease or surgery that may affect drug absorption * Positive or indeterminate QuantiFERON-TB Gold test at screening * Any active infection at the time of screening or admission